A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
Sponsor: GlaxoSmithKline
Listed as NCT00410384, this PHASE3 trial focuses on Systemic Lupus Erythematosus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Human Genome Sciences Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Arlington, United States, Atlanta, United States, Austin, United States, Aventura, United States, Bad Nauheim, Germany, Baltimore, United States, Barcelona, Spain, Baton Rouge, United States, Beersheba, Israel and 117 more location s